Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AstraZeneca Japan Grows 17% in 2022, Bags 12 Approvals; Up to 7 Filings Eyed for 2023
AstraZeneca enjoyed year-on-year sales growth of 17% in Japan in 2022, driven by new launches as well as its existing portfolio, country president Takafumi Horii said on April 13. The company snared a total of 12 Japanese approvals in the…
To read the full story
Related Article
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
- AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
- AstraZeneca to Drive Decarbonization by Bolstering EV Infrastructure in Japan
January 24, 2025
- AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
- AstraZeneca Japan Taps Ex-Takeda Japan Oncology Head as New Chief
July 4, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
BUSINESS
- Jardiance Takes Top Spot in Four Promotion Channels in July: Intage
September 9, 2026
- Rohto Develops Low-Concentration Azelaic Acid Formulation
September 9, 2026
- Kyowa Kirin’s nAMD Med Misses Mark in Global PII Study
September 9, 2026
- AstraZeneca, Kyushu Electric Power Unit Pilot EV Charging Service
September 9, 2026
- Kineret Could Bring Earlier Remission in Still’s Disease: Expert
September 8, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…